{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.21","value":"-2.4"},{"groupId":"OG001","spread":"5.27","value":"-1.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Physical Well-Being, EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.50","value":"-0.3"},{"groupId":"OG001","spread":"4.44","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Social/Family Well-Being, EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.59","value":"-1.4"},{"groupId":"OG001","spread":"3.93","value":"-0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Emotional Well-Being, EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.40","value":"-2.4"},{"groupId":"OG001","spread":"4.79","value":"-0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"Functional Well-Being, EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"The FACT-LYM includes the Functional Assessment of Cancer Therapy General Scale (FACT-G) and a 15-item lymphoma-specific subscale (LYM) over the past week. The FACT-G has 27 items that incorporate 4 scales including physical well-being (PWB; 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB; 6 items), and functional well-being (FWB; 7 items). The combined FACT-LYM instrument consists of a total of a 42 item questionnaire. Each question is answered on a 5- point scale of 0 (not at all) to 4 (very much) for a total possible score of 168. Higher scores indicate better well-being and a positive change from Baseline indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).","id":"OG000","title":"Alisertib"},{"description":"Pralatrexate 30 mg/m\\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).","id":"OG001","title":"Pralatrexate, or Romidepsin, or Gemcitabine"}],"paramType":"MEAN","populationDescription":"ITT population was defined as all participants who were randomized. The participants were analyzed according to the treatment they were randomized to receive, regardless of any errors of dosing.","reportingStatus":"POSTED","timeFrame":"Baseline and End of Treatment (EOT) (Up to 152 Weeks)","title":"Change Form Baseline in Reported Symptoms and Quality of Life (QoL) Assessment Per Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) for Functioning and Symptoms","type":"SECONDARY","unitOfMeasure":"score on a scale"}